CKD Bio Corp. (063160.KS)
KRW 22500.0
(-1.96%)
KRW 22500.0
(-1.96%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 143.29 Billion KRW | 6.72% |
| 2022 | 134.27 Billion KRW | 26.77% |
| 2021 | 105.91 Billion KRW | 35.13% |
| 2020 | 78.38 Billion KRW | 228.18% |
| 2019 | 23.88 Billion KRW | 439.38% |
| 2018 | -7.03 Billion KRW | 27.32% |
| 2017 | -9.68 Billion KRW | -147.36% |
| 2016 | -3.91 Billion KRW | -112.55% |
| 2015 | -1.84 Billion KRW | -2752.28% |
| 2014 | -64.56 Million KRW | -100.95% |
| 2013 | 6.82 Billion KRW | -40.59% |
| 2012 | 11.49 Billion KRW | -60.67% |
| 2011 | 29.22 Billion KRW | 1916.94% |
| 2010 | 1.44 Billion KRW | -47.74% |
| 2009 | 2.77 Billion KRW | -80.76% |
| 2008 | 14.4 Billion KRW | -40.96% |
| 2007 | 24.4 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 138.7 Billion KRW | -3.21% |
| 2024 Q1 | 143.3 Billion KRW | 0.01% |
| 2023 Q2 | 140.94 Billion KRW | 1.34% |
| 2023 Q3 | 151.84 Billion KRW | 7.73% |
| 2023 Q4 | 143.29 Billion KRW | -5.63% |
| 2023 FY | 143.29 Billion KRW | 6.72% |
| 2023 Q1 | 139.08 Billion KRW | 3.59% |
| 2022 Q3 | 120.78 Billion KRW | 9.91% |
| 2022 Q2 | 109.9 Billion KRW | 2.09% |
| 2022 FY | 134.27 Billion KRW | 26.77% |
| 2022 Q1 | 107.65 Billion KRW | 1.64% |
| 2022 Q4 | 134.27 Billion KRW | 11.16% |
| 2021 FY | 105.91 Billion KRW | 35.13% |
| 2021 Q2 | 95.84 Billion KRW | 5.99% |
| 2021 Q1 | 90.42 Billion KRW | 15.37% |
| 2021 Q4 | 105.91 Billion KRW | 2.2% |
| 2021 Q3 | 103.63 Billion KRW | 8.13% |
| 2020 Q4 | 78.38 Billion KRW | 1.51% |
| 2020 Q1 | 40.86 Billion KRW | 71.08% |
| 2020 Q2 | 59.23 Billion KRW | 44.97% |
| 2020 Q3 | 77.21 Billion KRW | 30.36% |
| 2020 FY | 78.38 Billion KRW | 228.18% |
| 2019 Q4 | 23.88 Billion KRW | 86.52% |
| 2019 FY | 23.88 Billion KRW | 439.38% |
| 2019 Q1 | 1.65 Billion KRW | 123.48% |
| 2019 Q2 | -236.83 Million KRW | -114.33% |
| 2019 Q3 | 12.8 Billion KRW | 5506.62% |
| 2018 FY | -7.03 Billion KRW | 27.32% |
| 2018 Q4 | -7.03 Billion KRW | 34.13% |
| 2018 Q3 | -10.68 Billion KRW | -9.15% |
| 2018 Q2 | -9.78 Billion KRW | 27.61% |
| 2018 Q1 | -13.52 Billion KRW | -39.65% |
| 2017 Q4 | -9.68 Billion KRW | -7.69% |
| 2017 FY | -9.68 Billion KRW | -147.36% |
| 2017 Q3 | -8.99 Billion KRW | -94.59% |
| 2017 Q2 | -4.62 Billion KRW | 9.42% |
| 2017 Q1 | -5.1 Billion KRW | -30.33% |
| 2016 Q2 | -7.18 Billion KRW | -87.89% |
| 2016 Q3 | -2.82 Billion KRW | 60.61% |
| 2016 FY | -3.91 Billion KRW | -112.55% |
| 2016 Q4 | -3.91 Billion KRW | -38.36% |
| 2016 Q1 | -3.82 Billion KRW | -107.57% |
| 2015 Q1 | -2.67 Billion KRW | -4046.48% |
| 2015 Q3 | -4.31 Billion KRW | -19.08% |
| 2015 Q2 | -3.62 Billion KRW | -35.23% |
| 2015 Q4 | -1.84 Billion KRW | 57.28% |
| 2015 FY | -1.84 Billion KRW | -2752.28% |
| 2014 FY | -64.56 Million KRW | -100.95% |
| 2014 Q4 | -64.56 Million KRW | -103.5% |
| 2014 Q3 | 1.84 Billion KRW | -52.68% |
| 2014 Q1 | 11.18 Billion KRW | 63.82% |
| 2014 Q2 | 3.9 Billion KRW | -65.12% |
| 2013 Q4 | 6.82 Billion KRW | -11.18% |
| 2013 FY | 6.82 Billion KRW | -40.59% |
| 2013 Q1 | 5.19 Billion KRW | -54.82% |
| 2013 Q2 | 7.89 Billion KRW | 51.95% |
| 2013 Q3 | 7.68 Billion KRW | -2.57% |
| 2012 Q2 | 23.64 Billion KRW | 2.08% |
| 2012 Q1 | 23.16 Billion KRW | -20.73% |
| 2012 Q3 | 17.22 Billion KRW | -27.15% |
| 2012 FY | 11.49 Billion KRW | -60.67% |
| 2012 Q4 | 11.49 Billion KRW | -33.27% |
| 2011 FY | 29.22 Billion KRW | 1916.94% |
| 2011 Q4 | 29.22 Billion KRW | 7.43% |
| 2011 Q3 | 27.2 Billion KRW | 45.42% |
| 2011 Q2 | 18.7 Billion KRW | -11.7% |
| 2011 Q1 | 21.18 Billion KRW | 1362.11% |
| 2010 Q1 | -1.39 Billion KRW | -150.46% |
| 2010 Q3 | 5.26 Billion KRW | 215.47% |
| 2010 Q4 | 1.44 Billion KRW | -72.47% |
| 2010 FY | 1.44 Billion KRW | -47.74% |
| 2010 Q2 | 1.66 Billion KRW | 219.23% |
| 2009 Q4 | 2.77 Billion KRW | -76.93% |
| 2009 FY | 2.77 Billion KRW | -80.76% |
| 2009 Q3 | 12.01 Billion KRW | -25.73% |
| 2009 Q2 | 16.18 Billion KRW | 25.81% |
| 2009 Q1 | 12.86 Billion KRW | -10.74% |
| 2008 Q1 | 24.02 Billion KRW | -1.55% |
| 2008 Q2 | 22.97 Billion KRW | -4.39% |
| 2008 Q3 | 20.16 Billion KRW | -12.21% |
| 2008 Q4 | 14.4 Billion KRW | -28.56% |
| 2008 FY | 14.4 Billion KRW | -40.96% |
| 2007 Q2 | 25.05 Billion KRW | 3.86% |
| 2007 FY | 24.4 Billion KRW | 0.0% |
| 2007 Q1 | 24.12 Billion KRW | 0.0% |
| 2007 Q4 | 24.4 Billion KRW | 1.27% |
| 2007 Q3 | 24.09 Billion KRW | -3.8% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -1527.949% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 74.949% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 53.905% |
| HANDOK Inc. | 283.45 Billion KRW | 49.447% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | -613.905% |
| Yuhan Corporation | -69.18 Billion KRW | 307.116% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 26.117% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 3987.776% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 72.331% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 541.837% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -89.358% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | -288.997% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | -73.65% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | -470.71% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -1527.949% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 189.646% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 28.689% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | 16.173% |
| JW Holdings Corporation | 480.68 Billion KRW | 70.189% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | 12.934% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -121821.588% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 7.174% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -5994.291% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | -522.988% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | 18.104% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | -175.704% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -1527.949% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | 9.476% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 59.993% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 7.174% |
| Yuhan Corporation | -69.18 Billion KRW | 307.116% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | -5.371% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | -140.131% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 66.609% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 7.174% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | -23.28% |
| Korea United Pharm Inc. | 16.42 Billion KRW | -772.422% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | -23.46% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 695.536% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 420.329% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -5994.291% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 66.111% |
| Boryung Corporation | 187.72 Billion KRW | 23.668% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 299.465% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -89.358% |
| JW Lifescience Corporation | 26.09 Billion KRW | -449.223% |